Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Equity Income: 2015-2024

Historic Equity Income for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Dec 2024 value amounting to -$8,000.

  • Lineage Cell Therapeutics' Equity Income rose 200.00% to $6,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $12,000, marking a year-over-year increase of 144.44%. This contributed to the annual value of -$8,000 for FY2024, which is 95.45% up from last year.
  • As of FY2024, Lineage Cell Therapeutics' Equity Income stood at -$8,000, which was up 95.45% from -$176,000 recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Equity Income ranged from a high of $3.1 million in FY2020 and a low of -$2.2 million during FY2022.
  • In the last 3 years, Lineage Cell Therapeutics' Equity Income had a median value of -$176,000 in 2023 and averaged -$792,667.
  • In the last 5 years, Lineage Cell Therapeutics' Equity Income slumped by 61.25% in 2020 and then soared by 95.45% in 2024.
  • Lineage Cell Therapeutics' Equity Income (Yearly) stood at $3.1 million in 2020, then reached -$2.2 million in 2022, then soared by 91.98% to -$176,000 in 2023, then soared by 95.45% to -$8,000 in 2024.